Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial

COMMENTED

Type 2 Diabetes

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial

Lancet Diabetes Endocrinol.

Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, White J, Tershakovec A, Braunwald E

doi: 10.1016/S2213-8587

COMMENTED

Type 2 Diabetes

Effects of zinc supplementation on lipid profile in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Nutr Metab Cardiovasc Dis.

Asbaghi O, Sadeghian M, Fouladvand F, Panahande B, Nasiri M, Khodadost M, Shokri A, Pirouzi A, Sadeghi O

doi: 10.1016/j.numecd.2020.03.021.

COMMENTED

Diabetes - GeneralType 2 Diabetes

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

Diabetes Care.

Lingvay I, Desouza CV, Lalic KS, Rose L, Hansen T, Zacho J, Pieber TR

doi: 10.2337/dc17-2381.

COMMENTED

Diabetes - GeneralType 2 DiabetesGlycemic Control

Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial

Diabetes Obes Metab.

Ridderstråle M, Rosenstock J, Andersen KR, Woerle HJ, Salsali A; EMPA-REG H2H-SU trial investigators

doi: 10.1111/dom.13457.

Type 2 DiabetesGlycemic Control

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

Diabetes Care.

Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O

doi: 10.2337/dc19-1745.

Type 2 DiabetesGlycemic Control

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes

Diabet Med.

Matthews DR, Paldánius PM, Proot P, Foley JE, Stumvoll M, Del Prato S

doi: 10.1111/dme.13886.

Diabetes - GeneralType 2 Diabetes

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

Diabetes Care.

Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA, LEADER Steering Committee, LEADER Trial Investigators

doi: 10.2337/dc16-2747.

Type 2 Diabetes

Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial

Diabetes Obes Metab.

Blonde L, Belousova L, Fainberg U, Garcia-Hernandez PA, Jain SM, Kaltoft MS, Mosenzon O, Nafach J, Palle MS, Rea R

doi: 10.1111/dom.13978.

COMMENTED

Diabetes - GeneralType 1 DiabetesType 2 DiabetesGlycemic Control

Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia

doi: 10.1007/s00125-017-4449-2.

Related content

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial

Effects of zinc supplementation on lipid profile in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial

Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia